Stock Events

Stock Events

Purple Biotech 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-13.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1YI0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes in developing treatments for cancer, a key area of focus for Purple Biotech.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech firm with a strong emphasis on oncology and inflammatory disease treatments, directly competing with Purple Biotech's cancer therapy development.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer and other diseases, making it a direct competitor.
Merck
MRK
Mkt Cap298.84B
Merck & Co. focuses on cancer drugs and vaccines, which aligns with Purple Biotech's mission to develop novel treatments for cancer.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical company with a broad portfolio that includes oncology, directly competing with Purple Biotech's cancer-focused therapies.
Novartis
NVS
Mkt Cap297.32B
Novartis is a healthcare company that engages in the research, development, and marketing of healthcare products, including cancer treatments, competing with Purple Biotech.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG is a pioneer in healthcare with a strong emphasis on oncology, making it a competitor in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cancer.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its innovative treatments in areas like oncology, directly competing with Purple Biotech's research and development efforts.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation specializes in oncology products, making it a competitor in the development of new cancer treatments.

About

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Show more...
CEO
ISIN
US74638P3073
WKN
000A423RM

Listings

TA
IL
PPBT.TA
BOATS
BOATS
PPBT.BOATS
XNAS
US
PPBT
F
DE
1YI0.F

0 Comments

Share your thoughts

FAQ

What is Purple Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Purple Biotech stocks are traded under the ticker 1YI0.F.
What is Purple Biotech revenue for the last year?▼
Purple Biotech revenue for the last year amounts to 0 EUR.
What is Purple Biotech net income for the last year?▼
1YI0.F net income for the last year is -13.72M EUR.
When did Purple Biotech complete a stock split?▼
The last stock split for Purple Biotech was on March 02, 2026 with a ratio of 1:10.